Immunocore
A leading T cell receptor (TCR) biotechnology company working to create first-in-class biological therapies to address unmet patient needs in oncology as well as infectious and autoimmune diseases.
HQ location
Milton, United Kingdom
Website
Launch date
Employees
Market cap
$1.6b
loading funding rounds…
Woodford Investment Management(exited)
RTW Investments(exited)
Eurostars SME programme(exited)
Eli Lilly(exited)
General Atlantic(exited)
CCB International(exited)
JDRF T1D Fund(exited)
Rock Springs Capital(exited)
Bill & Melinda Gates Foundation(exited)
BlackRock(exited)
NeoMed(exited)
Omega Funds(exited)
WuXi Healthcare Ventures(exited)
| GBP | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | (12 %) | 442 % | 74 % | (6 %) | 22 % | 7 % | 12 % |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | (509 %) | (25 %) | (15 %) | (9 %) | (18 %) | (28 %) | (26 %) |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | (496 %) | (29 %) | (22 %) | (16 %) | (10 %) | (17 %) | (16 %) |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| R&D % of revenue | 276 % | 62 % | 66 % | 72 % | - | - | - |
Source: Company filings or news article, Equity research estimates
Related Content
Analytics
Unlock the full power of analytics with a premium account
Track company size and historic growth
Track team composition and strength
Track website visits and app downloads
Tech stack
Tech stackLearn more about the technologies and tools that this company uses.